Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Western Alliance Bancorporation — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $5.07 (market cap $1.74B), while Western Alliance Bancorporation trades at $74.18 (market cap $8.24B). The key difference: Western Alliance Bancorporation is far larger — about 4.7× Nuvation Bio Inc. Class A Common Stock's market cap, and Western Alliance Bancorporation pays a 2.23% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 1 Days and Western Alliance Bancorporation for 3 Days on average.
| NUVB | WAL | |
|---|---|---|
Market Cap | $1.74B | $8.24B |
Volume | 9,289,619 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $9.54 | $96.08 |
52-Week Low | $3.41 | $66.70 |
Typical Hold Time | 1 Days | 3 Days |
Enterprise Value | $1.33B | $9.76B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Western Alliance Bancorporation (WAL) trades at $74.27, down 0.11% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.52 and net income margin of 25.43%, while recent earnings beat expectations in two of the last three quarters. Analyst consensus remains strongly bullish with a $84.33 price target, supported by institutional buying activity and positive business developments including the launch of WA VenueX platform.
WAL presents a compelling value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term weakness. Key risks include regulatory changes affecting banking thresholds and potential margin pressure from interest rate environment. The stock's 13.43% ROE and 79% analyst buy rating support long-term upside potential above current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
